Caroline Seymour | Authors

October 06, 2021

Most patients with advanced HCC have resistance to PD-1 monotherapy. In other cancers, response to PD-1 inhibitors has been associated with an inflamed microenvironment with effector T cells and active IFN-α signaling.

September 21, 2021

In patients with HER2-positive, metastatic colorectal cancer, fam-trastuzumab deruxtecan-nxki led to improved responses in patients with higher HER2 expression at baseline, whereas responses were seen irrespective of RAS- and PIK3CA mutation status and blood tumor mutational burden levels.

September 21, 2021

A safety analysis from the phase 3 ARAMIS trial showed that tolerability with darolutamide was comparable with that of placebo in patients with nonmetastatic castration-resistant prostate cancer.

September 19, 2021

Tisotumab vedotin elicited significant responses without prohibitive toxicity in combination with carboplatin as frontline therapy, as well as in combination with pembrolizumab as second- or third-line therapy in patients with recurrent or metastatic cervical cancer.

September 16, 2021

Mobocertinib displayed a manageable safety profile across 40-mg, 120-mg, and 160-mg dose cohorts, leading to the determination of 160 mg as the maximum tolerated dose and recommended phase 2 dose for further study in Japanese patients with non–small cell lung cancer.

September 09, 2021

Multiple new targets are being researched for the treatment of chronic lymphocytic leukemia, and experts a particularly excited about novel BTK inhibitors and cellular therapies.